Talanta 2012-11-15

Development and validation of a simple and sensitive high performance liquid chromatographic method for the simultaneous determination of anastrozole, bicalutamide, tamoxifen, and their synthetic impurities

Fabio Pereira Gomes, Pedro Lopez Garcia

Index: Talanta 101 , 495-503, (2012)

Full Text: HTML

Abstract

A simple and sensitive analytical method for simultaneous determination of anastrozole, bicalutamide, and tamoxifen as well as their synthetic impurities, anastrozole pentamethyl, bicalutamide 3-fluoro-isomer, and tamoxifen e-isomer, was developed and validated by using high performance liquid chromatography (HPLC). The separation was achieved on a Symmetry® C-8 column (100×4.6mm i.d., 3.5μm) at room temperature (±24°C), with a mobile phase consisting of acetonitrile/water containing 0.18% N,N dimethyloctylamine and pH adjusted to 3.0 with orthophosphoric acid (46.5/53.5, v/v) at a flow rate of 1.0mLmin−1 within 20min. The detection was made at a wavelength of 270nm by using ultraviolet (UV) detector. No interference peaks from excipients and relative retention time indicated the specificity of the method. The calibration curve showed correlation coefficients (r) >0.99 calculated by linear regression and analysis of variance (ANOVA). The limit of detection (LOD) and limit of quantitation (LOQ), respectively, were 2.2 and 6.7μgmL−1 for anastrozole, 2.61 and 8.72μgmL−1 for bicalutamide, 2.0 and 6.7μgmL−1 for tamoxifen, 0.06 and 0.22μgmL−1 for anastrozole pentamethyl, 0.02 and 0.07μgmL−1 for bicalutamide 3-fluoro-isomer, and 0.002 and 0.007μgmL−1 for tamoxifen e-isomer. Intraday and interday relative standard deviations (RSDs) were <2.0% (drugs) and <10% (degradation products) as well as the comparison between two different analysts, which were calculated by f test.


Related Compounds

  • Anastrozole
  • Bicalutamide

Related Articles:

Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.

2014-12-01

[Lancet Oncol. 15(13) , 1460-8, (2014)]

NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions.

2014-08-15

[Cancer Res. 74(16) , 4446-57, (2014)]

Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole.

2014-01-01

[J. Cancer Res. Clin. Oncol. 140(1) , 159-66, (2014)]

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.

2015-04-01

[Int. J. Oncol. 46(4) , 1481-90, (2015)]

Sex-dependent influence of endogenous estrogen in pulmonary hypertension.

2014-08-15

[Am. J. Respir. Crit. Care Med. 190(4) , 456-67, (2014)]

More Articles...